A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Program Lead - Development, Rare Disease

Biology & BiotechConfirmed live in the last 24 hours
Full-time$246.5k - $333.5k

About the Job

Requirements

  • An advanced degree in medicine, science, pharmacy, or a related discipline is required.
  • At least 10 years of progressively responsible biotechnology or pharmaceutical drug-development experience, including significant experience leading cross-functional development teams or complex development programs.
  • Experience with early-stage development, including first-in-human studies, Phase 1 development, proof-of-concept planning, and/or progression into Phase 2.
  • Broad understanding of the drug-development process and the interdependencies among clinical development, regulatory strategy, clinical operations, safety, biometrics, nonclinical development, chemistry, manufacturing and controls, and program management.
  • Experience developing integrated program strategies, evaluating development scenarios, and translating scientific and clinical evidence into program decisions.
  • Ability to rapidly build sufficient knowledge to lead programs in complex or evolving disease areas.
  • Ability to lead through influence, align stakeholders with differing perspectives, and drive decisions without relying on formal authority.
  • Ability to navigate ambiguity, identify key decisions and milestones, and create clarity for cross-functional teams.
  • Strong strategic judgment and willingness to work at a detailed, hands-on level when required.
  • Ability to anticipate future development needs and plan for program success while balancing evidence, risk, resources, and organizational priorities.
  • Ability to communicate complex program considerations clearly and persuasively to senior leaders and governance forums.
  • Commitment to patients, scientific rigor, integrity, accountability, and high performance.

Responsibilities

  • Lead development and execution of integrated, cross-functional strategies for early-stage rare disease programs.
  • Establish program vision, strategy, and prioritized milestones aligned with scientific, clinical, regulatory, operational, and business considerations.
  • Develop fit-for-purpose program plans reflecting each asset’s stage, evidence base, investment level, and future potential, while maintaining readiness to accelerate when emerging data support further development.
  • Lead cross-functional teams in defining proof-of-concept strategies, decision criteria, critical assumptions, and data requirements to evaluate therapeutic potential and inform investment decisions.
  • Integrate scientific evidence, clinical data, regulatory considerations, patient needs, and the evolving external landscape into program strategy and decision-making.
  • Translate complex and sometimes incomplete information into clear recommendations, priorities, and executable plans.
  • Anticipate program risks, barriers, and interdependencies; establish mitigation and contingency plans and escalate issues appropriately to support timely decisions.
  • Partner with functional leaders to align resources, capabilities, and subject-matter expertise with program milestones and deliverables.
  • Foster an inclusive, high-performing team environment that encourages rigorous debate, transparent communication, shared accountability, and timely decision-making.
  • Prepare and present program strategy, status, risks, scenarios, and recommendations to governance bodies and senior leadership.
  • Ensure key decisions, assumptions, dependencies, and program risks are clearly documented and communicated across the organization.
  • Serve as a visible and credible champion for the programs, articulating their scientific rationale, patient impact, strategic value, and development path.

Desired Qualifications

  • Experience in rare disease drug development.
  • MD, PhD, PharmD, or equivalent advanced scientific or clinical training.
  • Therapeutic-area flexibility and intellectual agility.
  • Collaborative, decisive, and adaptable leadership style with a commitment to data-driven decision-making.
  • Alignment with Alnylam’s Core Values: Fiercely Innovative, Open Culture, Passion for Excellence, Purposeful Urgency, and Commitment to People.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs